Publications by authors named "Jose Alfon"

Claim this Profile
T
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
David Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, Rubi Li, Diego Cortinovis, Jose Alfon

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
Joaquim Bosch-Barrera, Purificación Estévez-García, Paloma Martín-Martorell, Renaud Sabatier, Ernest Nadal

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Jose Alfon

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Jose Alfon

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Jose Alfon

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Jose Alfon

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.
Emma Polonio-Alcalá, Sònia Solé-Sánchez, Pau Muñoz-Guardiola, Elisabet Megías-Roda, Héctor Perez-Montoyo

Cancer Commun (Lond)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Pau Muñoz-Guardiola, Josefina Casas, Elisabet Megías-Roda, Sònia Solé, Héctor Perez-Montoyo

Autophagy· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
Laura Vidal, Ivan Victoria, Lydia Gaba, Marta Gil Martín, Mercè Brunet

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.
Laia París-Coderch, Aroa Soriano, Carlos Jiménez, Tatiana Erazo, Pau Muñoz-Guardiola

Cell Death Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
Anna López-Plana, Patricia Fernández-Nogueira, Pau Muñoz-Guardiola, Sònia Solé-Sánchez, Elisabet Megías-Roda

Int J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Isidre Felip, Cristian Pablo Moiola, Cristina Megino-Luque, Carlos Lopez-Gil, Silvia Cabrera, José Alfon

Gynecol Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.
Tatiana Erazo, Mar Lorente, Anna López-Plana, Pau Muñoz-Guardiola, Patricia Fernández-Nogueira

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.
Julio Cortijo, María-Jesús Sanz, Arantxa Iranzo, José Luis Montesinos, Yafa Naim Abu Nabah

Br J Pharmacol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Carmen Almansa, José Alfón, Alberto F de Arriba, Fernando L Cavalcanti, Ignasi Escamilla

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis